

New York State Medicaid Drug Utilization Review (DUR) Board Meeting Room 5, Concourse Level, Empire State Plaza, Albany NY April 20, 2023 10:00am to 2:00pm

The meeting will be available for public viewing as a live and archived webcast

Department of Health Events and Webcasts

Welcome and Introductions
Public Comment
Drug Utilization Review
The DUR Board will review the following drugs and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate utilization:
1. elivaldogene autotemcel (Skysona®)
2. etranacogene dezaparvovec-drlb (Hemgenix®)
Break
Procedures for Member Videoconferencing
The DUR Board will review and may adopt procedures to satisfy the requirement of Public Offers Law (POL) § 103-a(2)(b), which permits members of a public body to participate in meetings by videoconferencing from a non-public location in certain situations. Open Meetings Law
Pharmacy Program Updates
Pharmacy Program Updates The DUR Board will be provided update on the following topics:
The DUR Board will be provided update on the following topics: 1. The SUPPORT (Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and



The agenda timeline is subject to change based on meeting proceedings.

Interested parties must submit a request to provide public comment during the DUR Board meeting and must complete the registration process by April 12, 2023. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov (please reference DUR Board Meeting Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes), and the total comment period will not exceed sixty (60) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment to meet agenda timelines and accomplish meeting objectives.

Written statements must be received in an electronic format by April 12, 2023. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

Clinical information must be submitted in an electronic format by April 6, 2023, or the DUR Board may not have ample time to review the information.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.

Other Meeting Locations

University at Buffalo School of Pharmacy and Pharmaceutical Sciences Abbott Hall Buffalo. NY 14214

SUNY Global Center 116 East 55th Street, New York, NY 10022

St. John Fisher University James S. Alesi Academic Center Rochester, NY 14618